Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute – Lung Cancer
The state of knowledge regarding multimodality treatment for lung cancer is continually changing and it is important for surgeons, medical oncologists, radiation oncologists and pulmonologist to stay up to date on the latest recommendations for the management of the disease. The distinguished faculty from Baptist Health Miami Cancer Institute and Baptist Health Lynn Cancer Institute will discuss new advances in the management of lung cancer.
Target Audience
Internists, Hospitalists, General Practitioners, Pulmonologists, General Surgeons, Thoracic Surgeons, Obstetricians and Gynecologists, Oncologists, Radiation Oncologists, Nurses, Nurse Practitioners, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Develop selective strategies for determining the appropriate extent of resection for individual patients.
- Assess the outcomes of patients experiencing complications after robotic pulmonary resection.
- Identify treatment-related factors associated with an increased risk of major complications.
- Identify the benefits of robotic intervention versus thoracotomy or conventional VATS techniques.
- Describe the morbidity and mortality rates of complete resection associated with robotic surgery in the treatment of lung cancer.
- Identify the principles of stereotactic body radiotherapy for early-stage non-small cell lung cancer.
- Analyze and assess outcomes for nonoperative management of locally advanced non-small cell lung cancer.
- Accurately assess and execute a thorough workup of a solitary lung nodule.
- Differentiate and evaluate treatment approaches of a lung nodule versus sampled nodule and when to proceed with surgical resection.
- Evaluate bronchoscopic techniques, radial endobronchial ultrasound, navigation bronchoscopy, electromagnetic navigation and robotic platforms.
- Describe results of recent clinical trials that combine targeted therapies with chemotherapy.
- Implement strategies that optimize therapeutic decisions for patients based on individual molecular, genomic and clinical features.
- Analyze current strategies and standard of care for proper pretreatment of molecular and PDL-1 testing.
- Execute appropriate treatment with immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer.
- Integrate gene mapping into professional practice updates when treating lung cancer.
- Identify the most effective treatment plan as a result of gene mapping.
- Identify new treatments for resectable lung cancer.
Federico Albrecht, M.D.
Thoracic Oncology
Miami Cancer Institute
Miami, Florida
Federico Albrecht, M.D., faculty for this educational event, is on the speakers’ bureau for Lily Pharmaceutical, Guardant Health Lab and Boehringer Ingelheim. He is also an adviser for GI Therapeutic and Sanofi. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
John F. DeRosimo, M.D.
Thoracic Surgery
Miami Cancer Institute
Miami, Florida
John F. DeRosimo, M.D., faculty for this educational event, has individual stocks/stock options in Intuitive Surgical, Novo-Nordis, Ampio Pharmaceuticals, Cytodyne and Heat Biologics, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Mark Dylewski, M.D.
Chief of General Thoracic Surgery
Medical Director of Thoracic Robotic Surgery
Chairman of Thoracic Surgical Oncology
Miami Cancer Institute
Miami, Florida
Mark Dylewski, M.D., conference director for this educational event, is on the speakers’ bureau for Intuitive Surgical, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Paul Kaywin, M.D.
Thoracic Medical Oncologist
Miami Cancer Institute
Miami, Florida
Paul Kaywin, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Rupesh Kotecha, M.D.
Director of CNS Metastasis Program
Chief of Radiosurgery
Department of Radiation Oncology
Miami Cancer Institute
Miami, Florida
Rupesh Kotecha, M.D., faculty for this educational event, has received honorariums from Elekta AB, Accuray, ViewRay and Elsevier. He has also received research support from Medtronic, Blue Earth Diagnostics, Novocure, Exelixis, GT Medical, AstraZeneca and ViewRay. He is on the speakers’ bureau for Novocure and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Matthen Mathew, M.D.
Hematologic Oncology
Boca Raton Regional Hospital
Boca Raton, Florida
Matthen Mathew, M.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
John R. Roberts, M.D.
Thoracic Surgery
Lynn Cancer Institute
Boca Raton, Florida
John R. Roberts, M.D., faculty for this educational event, is a consultant with Scott Flora Consulting and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Andres F. Sosa, M.D.
Pulmonary and Critical Care Medicine
Miami Pulmonary Specialists
Miami, Florida
Andres F. Sosa, M.D., faculty for this educational event, is on the speakers’ bureau for GSK and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Raul R. Valor, M.D.
Clinical Assistant Professor
Herbert Wertheim College of Medicine
Florida International University
Chief, Department of Medicine
Baptist Hospital of Miami
Miami, Florida
Raul R. Valor, M.D., faculty for this educational event, is on the speakers’ bureau for GSK, Boehringer and AstraZeneca and is a consultant with Olympus. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
All of the relevant financial relationships listed for these individuals have been mitigated.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Surgery - Maintenance of Certification (MOC) - Accredited CME - Complex General Surgical Oncology
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
Your participation information will be shared with specialty boards through the ACCME's PARS reporting system. Successful completion of a course examination is required. Submissions are recorded in approximately 48 hours. You will receive an email when your credits have been processed.
Available Credit
- 2.75 ABS MOC II
- 2.75 AMA PRA Category 1 Credit™
- 2.75 General certificate of attendance
- 2.50 Nurse Practitioners
- 2.50 Florida Board of Nursing
Price
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
